Renal cell carcinoma treated by vaccines for active specific immunotherapy : correlation of survival with skin testing by autologous tumor cells

Eighteen patients with metastatic renal cell carcinoma, who were treated by vaccines for active specific immunotherapy, also completed skin testing with autologous tumor cells, both prior to and following vaccine treatment. All patients have now been followed for more than 5 years. Ten patients who...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Immunology Immunotherapy 1990-01, Vol.32 (1), p.62-66
Main Authors: MCCUNE, C. S, O'DONNELL, R. W, MARQUIS, D. M, SAHASRABUDHE, D. M
Format: Article
Language:English
Subjects:
Antineoplastic agents
Biological and medical sciences
Carcinoma, Renal Cell - immunology
Carcinoma, Renal Cell - mortality
Carcinoma, Renal Cell - pathology
Carcinoma, Renal Cell - therapy
Humans
Immunotherapy
Immunotherapy, Active
Kidney Neoplasms - immunology
Kidney Neoplasms - mortality
Kidney Neoplasms - pathology
Kidney Neoplasms - therapy
Medical sciences
Original
Pharmacology. Drug treatments
Retrospective Studies
Skin - drug effects
Skin - immunology
Skin Tests
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Eighteen patients with metastatic renal cell carcinoma, who were treated by vaccines for active specific immunotherapy, also completed skin testing with autologous tumor cells, both prior to and following vaccine treatment. All patients have now been followed for more than 5 years. Ten patients who remained skin-test-negative following treatment had no clinical responses, and all had expired by 22 months. Eight patients became skin-test-positive; three of these had clinical regressions and three remain alive after more than 69 months. The survival times of the skin-test-positive group were significantly superior to those of the skin-test-negative group. The results suggest that skin testing with autologous tumor cells may accurately identify those patients who have acquired antigen-specific cell-mediated antitumor immunity.
ISSN:0340-7004
1432-0851
DOI:10.1007/BF01741726